Experience
Elan Corp., PLC
Brightstone Pharma
Represented Elan in Hatch-Waxman litigation against Brightstone and SkyePharma relating to their intention to market generic copies of Naprelan®. Case settled on confidential terms.
Elan Corp., PLC v. Brightstone Pharma, 5:98-cv-00701, E.D.N.C., Judge Britt
A high-impact result for R&D licensing programs in the pharmaceutical industry
Elan Corporation PLC
Medtronic PLC
Wyeth
Aventis Pharma, S.A. v. Baxter Healthcare Corp.
Aventis Pharma, S.A.
PQ Corp. v. Johnson Matthey PLC
PQ Corp.
Synthon Pharmaceuticals, Inc. v. Eli Lilly and Co.
Eli Lilly and Co.; ICOS
Glenmark Generics Ltd. v. GlaxoSmithKline, PLC
GlaxoSmithKline, PLC
Drexler Technology Corp. v. Sony Corp.
Sony Corp.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.